It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that ...

Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...

Moderna Inc. said it will reduce its global workforce by roughly 10% before year’s end, responding to sharply reduced demand ...

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

To layoff 5,000 employees by the end of the year; aims to reduce operating expenses by approximately $1.5 billion by 2027.

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In t ...